Sign In
Free Newsletter
AG Frosh’s powers expanded during 2017 legislative session
Now that Maryland Attorney General Brian E. Frosh has the authority to sue the federal government, will he?
Trump may be more ‘vicious’ on drug prices, Allergan CEO says
Donald Trump‘s victory in the presidential race, often cited as a boon to free-market health care, doesn’t mean drugmakers are free of scrutiny over prices, an industry leader said. U.S. […]
Md. health care group urges support for anti-price gouging package
A Baltimore-based health care organization is proposing legislation to go after drug companies for price gouging, warning legislators of a poll it said shows voters are willing to make this an issue […]
CASI losses continued in 4th quarter
Rockville-based CASI Pharmaceuticals, Inc. reported a net loss of $1.6 million in its fourth-quarter numbers compared to a loss of $1.6 million for the same period last year. CASI, which […]
Emergent BioSolutions expands Baltimore facility
Emergent BioSolutions, a specialty biopharmaceutical company, is expanding its manufacturing facility in Baltimore, a move that is expected to bring 158 new jobs to the city over the next four years.
Sucampo expands deal with Japanese firm
Sucampo Pharmaceuticals Inc., of Bethesda, has reached a deal with Takeda Pharmaceutical Co. Ltd., of Japan, for expanded licensing, development and supplying of Amitiza, Sucampo’s treatment for chronic idiopathic constipation […]
RegeneRx nears eye-drop trials
RegeneRx Biopharmaceuticals Inc., of Rockville, may start clinical trials of a treatment for neurotrophic keratopathy, a disease of the cornea, within a year, the company announced. RegeneRx said it met […]
Tasly to launch headquarters in Rockville
Tasly Pharmaceuticals Inc. will hold a ribbon-cutting ceremony on Wednesday at its corporate offices in Rockville to mark the official launch of the North American headquarters of Tasly Holding Group, […]
Drug-maker: Indiana shouldn’t use our product for execution
The maker of a drug Indiana wants to use for its first execution since 2009 says the anesthetic, which has never been used in lethal injections, isn't approved for that purpose and that it only recently learned of the state's intentions.
Valeant’s offer to buy maker of Botox put at $45.6 billion
Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.
Rockville-based Rexahn Pharmaceuticals’ loss increases
Rexahn Pharmaceuticals Inc., of Rockville, reported a loss for 2013 that was more than double analysts’ forecasts.
EntreMed reports higher loss in 4Q
EntreMed Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported a fourth-quarter net loss of $1.3 million.
